Tumor cells harboring the BRAF600E mutation have shown similar resistance to MEK1/2 inhibitors “Figure 1” by increasing signaling through the ERK1/2 pathway due to amplification of the oncogene [13,22]. This evidence concerns the gene MAP2K1 and neoplasm.